Friday, 13 November 2026European Markets

NORWEGIAN AIR SHUT Stock Jumps By 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORWEGIAN AIR SHUT (Oslo Børs All-share Index_GI: NAS.OL) rose by a staggering 33.72% in 21 sessions from 7.77 kr to 10.39 kr at 01:40 EST on Monday, after three sequential sessions in a row of losses. Oslo Børs All-share Index_GI is jumping 0.37% to 1,418.24 kr, after three sequential sessions in a row of losses.

NORWEGIAN AIR SHUT's last close was 10.52 kr, 23.21% below its 52-week high of 13.70 kr.

About NORWEGIAN AIR SHUT

Norwegian Air Shuttle ASA, together with its subsidiaries, provides scheduled and charter airline services in Norway and internationally. As of December 31, 2021, the company operated a fleet of 70 aircraft. It is also involved in aircraft financing, leasing, and ownership activities; and cargo activities. Norwegian Air Shuttle ASA was founded in 1993 and is headquartered in Fornebu, Norway.

Earnings Per Share

As for profitability, NORWEGIAN AIR SHUT has a trailing twelve months EPS of 0.1 kr.

PE Ratio

NORWEGIAN AIR SHUT has a trailing twelve months price to earnings ratio of 103.9. Meaning, the purchaser of the share is investing 103.9 kr for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.48%.

Yearly Top and Bottom Value

NORWEGIAN AIR SHUT's stock is valued at 10.39 kr at 01:40 EST, way below its 52-week high of 13.70 kr and way higher than its 52-week low of 6.33 kr.

Sales Growth

NORWEGIAN AIR SHUT's sales growth for the current quarter is 168.8%.

Volume

Today's last reported volume for NORWEGIAN AIR SHUT is 6520695 which is 52.3% above its average volume of 3844970.

More news about NORWEGIAN AIR SHUT (NAS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com